Speak to one of our representatives today 0800 0668079 Monday - Friday, 9am - 5pm 
Speak to one of our representatives today 0800 0668079 Monday - Friday, 9am - 5pm
The content of this website has been developed by Napp Pharmaceuticals Limited for healthcare professionals.
Napp is responsible for the content of this website and is also the copyright owner/authorised user of the content.
Please select an option to continue:
Please take me to the Napp healthcare professional website
Reporting adverse events
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Napp Pharmaceuticals Limited at
drugsafetyuk@napp.co.uk.
Please take me to napp.co.uk
Reporting adverse events
If you get any side-effects, talk to your doctor, nurse or pharmacist. This includes any possible side-effects not listed in the package leaflet. You can also report side-effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard. By reporting side-effects you can help provide more information on the safety of this medicine.
This webpage contains promotional information regarding Napp products. The content has been reviewed ny Napp to ensure compliance with the ABPI code of practice for the pharmaseutical industry.
About Napp
We’re in the business of bringing medicines to the NHS. It is work that deeply affects the lives of health providers and patients – and here at Napp we pride ourselves on doing it the right way.
The UK is not just our market, it’s our home. We’re a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK healthcare professionals and their patients.
Please visit us regularly to find the latest information.
Therapy Areas
- Biosimilars
- Cardiovascular
- Diabetes
- Oncology
- Pain Management & Supportive Care
- Respiratory
Important Safety Information
- Long-term use of opioid medicines carries an increased risk of dependence and addiction
- Discuss with patients that prolonged use of opioids may lead to drug dependence and addiction, even at therapeutic doses
- Before starting treatment with opioids, agree with the patient a treatment strategy and plan for end of treatment
- Opioid medicines and benzodiazepines (or benzodiazepine-like drugs) can both cause respiratory depression. When used together, additive effects on the central nervous system increase the risks of sedation, respiratory depression, coma, and death. Only prescribe opioids and benzodiazepines (or benzodiazepine-like drugs) together if there is no alternative
- For further information, please refer to product prescription information and advice for healthcare professionals https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction AND https://www.gov.uk/drug-safety-update/benzodiazepines-and-opioids-reminder-of-risk-of-potentially-fatal-respiratory-depression
Therapy Areas
Important Safety Information
- Long-term use of opioid medicines carries an increased risk of dependence and addiction
- Discuss with patients that prolonged use of opioids may lead to drug dependence and addiction, even at therapeutic doses
- Before starting treatment with opioids, agree with the patient a treatment strategy and plan for end of treatment
- Opioid medicines and benzodiazepines (or benzodiazepine-like drugs) can both cause respiratory depression. When used together, additive effects on the central nervous system increase the risks of sedation, respiratory depression, coma, and death. Only prescribe opioids and benzodiazepines (or benzodiazepine-like drugs) together if there is no alternative
- For further information, please refer to product prescription information and advice for healthcare professionals https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction AND https://www.gov.uk/drug-safety-update/benzodiazepines-and-opioids-reminder-of-risk-of-potentially-fatal-respiratory-depression
Events & Resources
Upcoming Events
- Upcoming Events
- On Demand
- Articles
- Other Resources
On Demand
Recent Data Transforming the Management of Kidney Disease in Patients with Type 2 Diabetes
T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.
In this video, Dr. Davies will discuss the unmet needs of slowing down kidney disease progression in type 2 diabetes, and the therapeutic innovation with data on the SGLT2 inhibitors.
Dr. Sarah Davies
MBBCh (hons), FRCP, MRCGP, PGDip
Clinical Director for Diabetes in Primary Care
for Cardiff and Vale University Health Board
English
0:10:21
Diabetes
webinar
T2DM Expert Talks, Promotional Content
- T2DM Expert Talks, Promotional Content
Recent Data Transforming the Management of Kidney Disease in Patients with Type 2 Diabetes
T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.
In this video, Dr. Wheeler will share his thoughts on how the recent data from SGLT2 inhibitors is driving the therapeutic innovation in the management of kidney disease in patients with type 2 diabetes.
Dr. David Wheeler, MBChB, MRCP, MD, FRCGP
Professor of Kidney Medicine at University College London and Honorary
Consultant Nephrologist at the Royal Free London NHS Foundation Trust, UK
- English
- 0:05:17
-
Diabetes
- webinar
- T2DM Expert Talks, Promotional Content
- T2DM Expert Talks, Promotional Content
Perspectives on Diabetes & CKD by Healthcare Professional
This non-promotional video from Jane Diggle covers her perspectives on diabetes and chronic kidney disease and why it’s such an important topic for people with type 2 diabetes.
Jane Diggle,
Practice nurse with specialist interest
in diabetes, West Yorkshire
Importance of early screening and diagnosis of CKD in T2DM
This paper reviews the burden of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and describes how clinicians can best utilise early screening and diagnosis together with renal protective therapies to improve patient outcomes.
Subgroup analysis of CREDENCE trial on the effects of canagliflozin on heart failure and CV death
In the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, canagliflozin demonstrated a risk reduction for hospitalisation for heart failure (HHF) or cardiovascular (CV) death by 31% (HR 0.69, 95% CI 0.57-0.83, P=0.0001). In this paper the authors explore the effect of canagliflozin on HHF/CV death stratifying the CREDENCE population according to different clinical characteristics.
Empagliflozin effects in patients with heart failure
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown reduction in hospitalisation for heart failure (HHF) and serious adverse renal events risks, beyond their glucose-lowering benefits. More specifically, patients with type 2 diabetes who received SGLT2 inhibitors in large-scale, randomised, placebo-controlled trials experienced a 30% to 35% lower risk of HHF compared with patients who received placebo, even though most of them did not have a history of heart failure at baseline.
Monthly newsletter
Bringing you the latest publications in type 2 diabetes mellitus selected by our panel of specialists.
